Recombinant Human CD19 Fc Chimera Avi-tag Protein, CF

AVI9269 Datasheet / COA / SDS

Biotinylated. Earn double rewards for reviews

Catalog #	Availability	Size / Price	Qty
AVI9269-050

Bulk Orders

Recombinant Human CD19 Fc Chimera Avi-tag Protein Binding Activity

2 Images

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CD19 Fc Chimera Avi-tag Protein, CF Summary

Find the full range of Avi-tag and amine biotinylated proteins

Avi-tag Proteins

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Human CD19 Antibody (FMC63) (Novus Biologicals, Catalog # NBP2-52716) is immobilized at 0.5 µg/mL (100 µL/well), it binds to Biotinylated Recombinant Human CD19 Fc Chimera Avi-tag (Catalog # AVI9269) with an ED₅₀ of 7.5-45 ng/mL.

Source

Chinese Hamster Ovary cell line, CHO-derived human CD19 protein

Human CD19 (Glu21- Lys291) Accession # P15391	IEGRMD	Human IgG₁ (Pro100 - Lys330)	Avi-tag
N-terminus			C-terminus

N-terminal Sequence
Analysis

Glu21

Structure / Form

Disulfide-linked homodimer, biotinylated via Avi-tag

Predicted Molecular Mass

59 kDa

SDS-PAGE

75-95 kDa, under reducing conditions

Product Datasheets

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

AVI9269

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Data Images

Binding Activity

View Larger

When Human CD19 antibody (FMC63) (Novus Biologicals Catalog # NBP2-52716) is immobilized at 0.5 μg/mL, 100 μL/well, Recombinant Human CD19 Fc Chimera Avi-tag (Catalog # AVI9269) binds with an ED₅₀of 7.5-45 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Recombinant Human CD19 Fc Chimera Avi-tag (Catalog # AVI9269) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 75-95 kDa and 150-190 kDa, respectively.

Reconstitution Calculator

Background: CD19

CD19 is a 95 kDa transmembrane glycoprotein that plays a central role in B cell activation and humoral immune responses (1, 2). Mature human CD19 consists of a 272 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 22 aa transmembrane segment, and a 243 aa cytoplasmic domain (3). Within the ECD, human CD19 shares 57% amino acid sequence identity with mouse and rat CD19. CD19 is expressed throughout B cell development from pre-B cells through mature B cells, and it is commonly used as a B cell lineage marker (1). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (4, 5). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu13, (6-9). These associations enable CD19 to amplify B cell signaling (7, 9-12) and reduce the threshold for antigen stimulation through the BCR (13). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2).

References

Wang, K. et al. (2012) Exp. Hematol. Oncol. 1:36.
Tedder, T.F. et al. (1997) Immunity 6:107.
Tedder, T.F. and C.M. Isaacs (1989) J. Immunol. 143:712.
Rickert, R.C. et al. (1995) Nature 376:352.
Engel, P. et al. (1995) Immunity 3:39.
Vences-Catalan, F. et al. (2012) J. Immunol. 137:48.
Deaglio, S. et al. (2007) Blood 109:5390.
Bradbury, L. et al. (1992) J. Immunol. 149:2841.
Krop, I. et al. (1996) J. Immunol. 157:48.
O'Rourke, L.M. et al. (1998) Immunity 8:635.
Buhl, A.M. et al. (1997) J. Exp. Med. 186:1897.
Sato, S. et al. (1995) Proc. Natl. Acad. Sci. USA 92:11558.
Carter, R.H. and D.T. Fearon (1992) Science 256:105.

Entrez Gene IDs

930 (Human); 12478 (Mouse); 365367 (Rat); 397669 (Porcine); 607898 (Canine); 102145514 (Cynomolgus Monkey); 100147468 (Equine)

Alternate Names

B4; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CD19 antigen; CD19 molecule; CD19; CVID3; Differentiation antigen CD19; Leu-12; MGC12802; T-cell surface antigen Leu-12